Nano cancer barrier device (NCBD) to immobilize and inhibit the division of metastic cancer stem cells

Patent metadata

Field	Value
Publication number	US-9439941-B2
Application number	US-96770810-A
Country	US
Kind code	B2
Filing date	Dec 14, 2010
Priority date	Dec 14, 2009
Publication date	Sep 13, 2016
Grant date	Sep 13, 2016

Abstract

The present invention provides methods, compositions, and kits wherein nanomaterials are used for inhibiting cancer stem cell division, colony formation, spheroid formation and self-renewal. The present invention also provides methods, compositions, and kits wherein nanomaterials are used for treating cancer, coating tumors, and inhibiting metastasis. The present invention also provides methods, compositions, and kits wherein nanomaterials are used for inducing cells to go into stasis. The present invention further provides methods for isolating tumors, inhibiting bleeding, and marking margins of tumors and organs during surgery with a nanomaterial.

First claim

What is claimed is:

1. A method for inducing cell stasis, comprising
(a) contacting the exterior surface of at least one cell with an effective amount of self-assembling peptides to completely surround the cell,
wherein the self-assembling peptides have a length of 8 to 200 amino acid residues conforming to one or more of Formulas I-IV:

((Xaa + -Xaa neu ) x (Xaa − -Xaa neu ) y ) n,
(I)

((Xaa neu -Xaa + ) x (Xaa neu -Xaa− ) y ) n,
(II)

((Xaa neu -Xaa − ) x (Xaa neu -Xaa + ) y ) n
(III)

((Xaa − -Xaa neu ) x (Xaa + -Xaa neu ) y ) n,
(IV)

wherein Xaa + is an amino acid residue having a positive charge; Xaa − is an amino acid residue having a negative charge; Xaa neu is an amino acid residue having a neutral charge; x and y are integers having a value of 1, 2, or 4, independently; and n is an integer having a value from 1 to 10; and
wherein the self-assembling peptides are not substantially self-assembled; and
(b) inducing assembly of the self-assembling peptides, to form a self-assembled structure that encapsulates the cell.

2. The method of claim 1 , wherein the cell is a cancer stem cell, wherein division, spheroid formation, or self-renewal of the cancer stem cell is inhibited.

3. The method of claim 1 , wherein the self-assembling peptides comprise the amino acid sequence RADARADARADARADA.

4. The method of claim 2 , wherein the cancer stem cell is a prostate cancer stem cell.

5. The method of claim 2 , wherein inducing stasis inhibits metastasis of the cancer cell.

6. The method of claim 1 , wherein self-assembling peptides are in solution at a concentration of between 1% weight to volume and 3% weight to volume.

7. The method of claim 5 , wherein the cancer cell is a prostate cancer cell.

8. The method of claim 5 , wherein the cancer cell is a cancer stem cell.

9. The method of claim 1 , wherein the cell is a vertebrate cancer stem cell.

10. The method of claim 1 , wherein the cell is in a tumor.

11. The method of claim 10 , wherein the tumor is a prostate tumor.

12. The method of claim 1 , wherein the cell is a cancer cell.

13. The method of claim 12 , further comprising treating the cancer with radiation or freezing.

14. The method of claim 10 , further comprising treating the tumor with radiation or freezing.

15. The method of claim 12 , further comprising treating the cancer with radiation.

16. The method of claim 12 performed before, during, or after a surgical procedure, the method further comprising:
introducing a metastasis-inhibiting effective amount of the self-assembling peptides at the area of surgical procedure; and
performing the surgical procedure,
whereby the self-assembling peptides surround the cancer cells and inhibit release of the cancer cells into the area of surgical procedure, thereby inhibiting metastasis.

17. The method of claim 16 , wherein the surgical procedure is a biopsy.

18. The method of claim 1 , wherein Xaa + is selected from arginine, lysine, and histidine.

19. The method of claim 1 , wherein Xaa − is selected from aspartic acid and glutamic acid.

20. The method of claim 1 , wherein Xaa neu is selected from alanine, valine, leucine, isoleucine, and glycine.

Assignees

• Ellis-Behnke Rutledge
• Ling Patrick Ming Tat
• Univ Hong Kong

Inventors

• Ellis-Behnke Rutledge
• Ling Patrick Ming Tat

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61K38/10 Primary

  Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title

• A61K38/08

  Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title

• A61P7/04

  Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title

• B82Y5/00

  Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery · CPC title